Skip to main content

Omission of Completion Axillary-Lymph-Node Dissection Noninferior

Medically reviewed by Carmen Pope, BPharm. Last updated on April 4, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, April 4, 2024 -- For patients with clinically node-negative breast cancer with sentinel-node macrometastases, the omission of completion axillary-lymph-node dissection is noninferior to more extensive surgery, according to a study published in the April 4 issue of the New England Journal of Medicine.

Jana de Boniface, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a noninferiority trial involving patients with clinically node-negative primary T1 to T3 breast cancer with one or two sentinel-node macrometastases. Participants were randomly assigned to completion axillary-lymph-node dissection or its omission. A total of 2,766 patients were enrolled across five countries between January 2015 and December 2021; the per-protocol population included 2,540 patients: 1,335 and 1,205 were assigned to undergo sentinel-node biopsy only and completion axillary-lymph-node dissection, respectively.

Radiation therapy, including nodal target volumes, was administered to 89.9 and 88.4 percent of patients in the sentinel-node biopsy-only group and the dissection group, respectively. Patients were followed for a median of 46.8 months. The researchers found that 191 patients had recurrence or died. The estimated five-year recurrence-free survival was 89.7 and 88.7 percent in the sentinel-node biopsy-only group and the dissection group, respectively, with a country-adjusted hazard ratio of 0.89 (95 percent confidence interval, 0.66 to 1.19), which was significantly below the prespecified noninferiority margin.

"The estimated five-year recurrence-free survival after sentinel-node biopsy only was noninferior to that after completion axillary-lymph-node dissection among patients with breast cancer and one or two sentinel-node macrometastases," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

Resistance Exercise Boosts Outcomes After Early-Stage Breast Cancer Surgery

FRIDAY, June 7, 2024 -- Early resistance exercise following surgery for early-stage breast cancer improves shoulder range of motion (ROM) and strength at one month and six months...

ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma

WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...

Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia

MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.